Coronary Artery Disease Clinical Trial
Official title:
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting
Reactive platelet hyperactivity following coronary artery bypass grafting (CABG) might lead
to thrombotic complications and major ischemic cardiac events. The aim of this study is to
evaluate the changes in platelet reactivity following CABG and to clarify a potentially
beneficial effect of dual antiplatelet therapy in the group of patients with documented
aspirin resistance following CABG. Platelet function will be assessed by multiple electrode
aggregometry. Aortocoronary vein graft disease is comprised of three distinct but
interrelated pathological processes: thrombosis, intimal hyperplasia and atherosclerosis.
Early vein thrombosis is a major cause of vein graft attrition during the first month after
CABG.
Bypass patency can be improved with antiplatelet therapy which is the mainstay of treatment
for patients after CABG. A beneficial effect of acetylsalicylic acid (ASA) on vein graft
patency has been previously shown. Some patients experience thrombotic events despite
continuous aspirin administration after CABG. The investigators hypothesized that low
responsiveness to aspirin might be a precipitating factor for adverse thrombotic events
following CABG.
Low responsiveness to ASA, as assessed by platelet function tests, varies widely among
patients. The etiology of postoperative platelet hyperactivity remains to be elucidated.
In this study a new point-of-care assay named multiple electrode aggregometry (MEA) using a
device called Multiplate analyzer (Dynabyte, Munich, Germany) has been utilized. It allows
for rapid and standardized assessment of platelet function parameters.
This is a prospective randomized trial. The aim of the study is to document whether
introduction of dual antiplatelet therapy in patients with ASA resistance will lead to a
lower incidence of major adverse cardiac events (MACE) at a six month follow up. The
composite endpoint will include death, non-fatal myocardial infarction, stroke and cardiac
rehospitalization. All patients will receive 300 mg of ASA starting 6 hours after surgery,
provided that the chest tube output is minimal. On postoperative day 4 their platelet
function will be assessed using the above mentioned MEA. The patients found to be aspirin
resistant will then undergo the process of randomization. The first arm will include
patients with ASA resistance in whom no additional antiaggregation will be administered. In
the second arm the investigators will include patients who were randomized to receive 75 mg
of clopidogrel in addition to the standard antiplatelet regimen of 300 mg of ASA.
Platelet function monitoring allows for individual tailoring of the antiplatelet therapy.
The goal of this study is to define whether this strategy will lead to improved patient
outcomes. Both major and minor bleeding complications will be strictly monitored and
reported.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |